| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2002;21:1080-1086
© 2002 Elsevier Science NL
a Department of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
b Department of Thoracic Surgery, Sainte Marguerite University Hospital, Marseille, France
c Department of Thoracic Surgery, Hotel-Dieu Hospital, Paris, France
d Department of Thoracic Surgery, National Cancer Center, Tokyo, Japan
Received 15 September 2001; received in revised form 17 January 2002; accepted 15 March 2002.
* Corresponding author. Fax: +39-2-57489698
e-mail: lorenzo.spaggiari{at}ieo.it
Objectives: Superior vena cava (SVC) resection with prosthetic replacement for non-small cell lung cancer (NSCLC) is infrequently performed and oncological results are unclear. To establish a historical benchmark for this extended surgery, we have updated and reviewed data from four international centers. Methods: Data were obtained through retrospective chart review. Prognostic factors were analyzed using first univariate techniques and subsequently multiple regression (logistic regression). Kaplan–Meier overall survival was calculated and prognostic factors examined by log–rank test and the estimation of hazard ratios using Cox regression. Results: From 1985 to 2000, 28 patients underwent SVC resection with prosthetic replacement for NSCLC. During the same period, 65 patients underwent partial SVC resection. Induction treatment was performed in 25% of patients. The resection was done for T involvement in 22 patients (79%), and for N2 involvement in the remaining. There were 12 tracheal sleeve resections, four pneumonectomies, and 12 lobar or sublobar resections with or without bronchoplasty. The median clamping time was 40 min. The median diameter of the prosthesis used was No. 14. Pathological examination showed direct SVC invasion (T4) in 79% of patients, whereas N2 disease was present in 50% of patients. Median intensive care unit and hospital stay were 3 and 20 days, respectively. The postoperative morbidity and mortality were 39 and 14%, respectively. The overall 5-year probability of survival was 15% (median of 9 months, range 0–105 months). Patients who underwent partial SVC resection during the same period had a significantly higher probability of survival (P=0.03). Induction chemotherapy was associated with a significant increase of postoperative morbidity in multivariate analysis. None of the potential prognostic factors analyzed in multivariate analysis were associated with survival, but the type of resection (sleeve pneumonectomy/pneumonectomy) were borderline significant. Conclusions: SVC resection with prosthetic replacement should not be considered an absolute contraindication in patients with NSCLC; however, the poor oncological results suggest more restrictive and severe criteria of patient selection (mediastinoscopy, induction treatment, no pneumonectomy, no N2 disease).
Key Words: Extended resection • Superior vena cava resection • Prosthesis replacement • Lung cancer • Advanced lung cancer • Stage IIIB • Polytetrafluoroethylene
This article has been cited by other articles:
|
|
 |
|
  B. Yildizeli, P. G. Dartevelle, E. Fadel, S. Mussot, and A. Chapelier Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: the benefit is worth the risk. Ann. Thorac. Surg., October 1, 2008; 86(4): 1065 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Lu, F. L. Yu, and Z. S. Wu Superior vena cava reconstruction using bovine jugular vein conduit Eur. J. Cardiothorac. Surg., November 1, 2007; 32(5): 816 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Spaggiari, F. Leo, G. Veronesi, P. Solli, D. Galetta, B. Tatani, F. Petrella, and D. Radice Superior Vena Cava Resection for Lung and Mediastinal Malignancies: A Single-Center Experience With 70 Cases Ann. Thorac. Surg., January 1, 2007; 83(1): 223 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Spaggiari, F. Petrella, F. Leo, G. Veronesi, P. Solli, A. Borri, D. Galetta, R. Gasparri, and P. Scanagatta Superior vena cava resection for lung and mediastinal malignancies MMCTS, October 9, 2006; 2006(1009): 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Spaggiari, D. Galetta, G. Veronesi, F. Leo, R. Gasparri, F. Petrella, A. Borri, G. Pelosi, and M. Venturino Superior vena cava replacement for lung cancer using a heterologous (bovine) prosthesis: Preliminary results J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 490 - 491. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. DiPerna and D. E. Wood Surgical Management of T3 and T4 Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5038s - 5044s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Suzuki, H. Asamura, S.-i. Watanabe, and R. Tsuchiya Combined Resection of Superior Vena Cava for Lung Carcinoma: Prognostic Significance of Patterns of Superior Vena Cava Invasion Ann. Thorac. Surg., October 1, 2004; 78(4): 1184 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Spaggiari, G. Veronesi, M. D'Aiuto, and A. Tosoni Superior vena cava reconstruction using heterologous pericardial tube after extended resection for lung cancer Eur. J. Cardiothorac. Surg., September 1, 2004; 26(3): 649 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Spaggiari, P. Solli, G. Veronesi, and U. Pastorino Intrathoracic myoplasty for prosthesis infection after superior vena cava replacement for lung cancer Ann. Thorac. Surg., October 1, 2002; 74(4): 1231 - 1233. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
